[go: up one dir, main page]

AR002971A1 - COMPUESTOS DE 3-(1,2,3,6)-TETRAHIDROPIRIDIN-4-ILO Y 3-PIPERIDIN-4-ILO-1H- INDOL, AGONISTAS DE 5HT(1f) FORMULACIONES FARMACEUTICAS QUE LOS CONTIENEN YMETODOS PARA ACTIVAR DICHOS RECEPTORES 5HT(1f) Y/O PARA TRATAR LAS MIGRANAS Y DESORDENES ASOCIADOS CON ELLA. - Google Patents

COMPUESTOS DE 3-(1,2,3,6)-TETRAHIDROPIRIDIN-4-ILO Y 3-PIPERIDIN-4-ILO-1H- INDOL, AGONISTAS DE 5HT(1f) FORMULACIONES FARMACEUTICAS QUE LOS CONTIENEN YMETODOS PARA ACTIVAR DICHOS RECEPTORES 5HT(1f) Y/O PARA TRATAR LAS MIGRANAS Y DESORDENES ASOCIADOS CON ELLA.

Info

Publication number
AR002971A1
AR002971A1 ARP960101828A AR10182896A AR002971A1 AR 002971 A1 AR002971 A1 AR 002971A1 AR P960101828 A ARP960101828 A AR P960101828A AR 10182896 A AR10182896 A AR 10182896A AR 002971 A1 AR002971 A1 AR 002971A1
Authority
AR
Argentina
Prior art keywords
alkyl
substituted
receptors
phenyl
ilo
Prior art date
Application number
ARP960101828A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR002971A1 publication Critical patent/AR002971A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se trata de nuevos agonistas de los receptores 5HT de fórmula (I), donde: A-B es -CH-CH2- ó -C=CH-; R y R es H ó alquilo:X es -S-R, -C(O)R3,-C(O)NR4R15,-NR5R6, -NR7SO2R8, --NHC(Q)NR10R11, -NHC(O)OR12 ó NR13C(O)R14; en donde Q es O ó S; R2 es fenilo substituido o no piridinilo; R3 es alquilo; fenilo alquilenosustituido o no en el fenilo, naftilo, N-metilo-N-metoxiamino, heteroarilo substituido o no; R4 es heteroarilo substituido o no; R4 y R5 tomados juntosforman un anillo de pirrolidina,piperidina, piperidina substituida, morfolino o tiomorfolino; R5 y R6 son ambos trifluorometanosulfonilo; R7 es H o alquilo;R8 es alquilo, fenilo substituido o no, o (di alquilo)amino; R10 y R11 son alquilo, alquenilo, cicloalquilo, fenilo sustituido o no, alquilo -alcoxicarboniloalquilfenilo, C1-C4 alquilo alfa substituido con C1-C4 alcoxicarbonil; ó R10 y R11 tomados juntos forman pirrolidina, piperidona,piperazina, piperazina 4-substituida, morfolino o tiomorfolino; R2 es alquilo, alquenil, fenilo substituido o no cicloalquilo, alcoxialquilo; R13 es H oalquilo; R14 es entre otros alquilo substituido con hasta 3 hidroxi, alcoxi, halo, ariloxi, alquiloxicarbonilo y heteroariloxi, alquenilo, alquinilo,cicloalquilo, fenilo substituido o no, naftilo, cicloalquilo, o un heterociclo; R15 es H o alquilo; sujeto a que cuando R7 es H, R8 no es alquilo. Losreceptores 5HT son útiles en el tratamiento de las migranas y desórdenes asociados con la misma. También se proponen: composiciones farmacéuticasformuladas con dichos compuestos como agente activo para el tratamiento de enfermedades que requieran la activación de dichos receptores y/o lainhibición del extravasado de péptidos para tratar dichos trastornos
ARP960101828A 1995-03-20 1996-03-20 COMPUESTOS DE 3-(1,2,3,6)-TETRAHIDROPIRIDIN-4-ILO Y 3-PIPERIDIN-4-ILO-1H- INDOL, AGONISTAS DE 5HT(1f) FORMULACIONES FARMACEUTICAS QUE LOS CONTIENEN YMETODOS PARA ACTIVAR DICHOS RECEPTORES 5HT(1f) Y/O PARA TRATAR LAS MIGRANAS Y DESORDENES ASOCIADOS CON ELLA. AR002971A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40755395A 1995-03-20 1995-03-20

Publications (1)

Publication Number Publication Date
AR002971A1 true AR002971A1 (es) 1998-05-27

Family

ID=23612560

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960101828A AR002971A1 (es) 1995-03-20 1996-03-20 COMPUESTOS DE 3-(1,2,3,6)-TETRAHIDROPIRIDIN-4-ILO Y 3-PIPERIDIN-4-ILO-1H- INDOL, AGONISTAS DE 5HT(1f) FORMULACIONES FARMACEUTICAS QUE LOS CONTIENEN YMETODOS PARA ACTIVAR DICHOS RECEPTORES 5HT(1f) Y/O PARA TRATAR LAS MIGRANAS Y DESORDENES ASOCIADOS CON ELLA.

Country Status (25)

Country Link
US (2) US5708008A (es)
EP (1) EP0733628B9 (es)
JP (1) JPH11502816A (es)
KR (1) KR19980703048A (es)
CN (1) CN1184425A (es)
AR (1) AR002971A1 (es)
AT (1) ATE198332T1 (es)
AU (1) AU702322B2 (es)
BR (1) BR9601061A (es)
CA (1) CA2215322A1 (es)
CZ (1) CZ288897A3 (es)
DE (1) DE69611315T2 (es)
DK (1) DK0733628T3 (es)
EA (1) EA001113B1 (es)
ES (1) ES2153078T3 (es)
GR (1) GR3035487T3 (es)
HU (1) HUP9800417A3 (es)
MX (1) MX9706969A (es)
NO (1) NO974220L (es)
NZ (1) NZ305166A (es)
PL (1) PL322843A1 (es)
PT (1) PT733628E (es)
SI (1) SI0733628T1 (es)
TR (1) TR199700993T1 (es)
WO (1) WO1996029075A1 (es)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9615658D0 (en) * 1996-07-25 1996-09-04 Merck Sharp & Dohme Therapeutic agents
US5962473A (en) * 1996-08-16 1999-10-05 Eli Lilly And Company Methods of treating or ameliorating the symptoms of common cold or allergic rhinitis with serotonin 5-HT1F
WO1998011895A1 (en) * 1996-09-18 1998-03-26 Eli Lilly And Company A method for the prevention of migraine
US5792763A (en) * 1996-10-08 1998-08-11 Eli Lilly And Company Serotonin 5-HT1F agonists
ZA979961B (en) * 1996-11-15 1999-05-05 Lilly Co Eli 5-HT1F agonists
EP1082958A3 (en) * 1996-11-15 2002-12-11 Eli Lilly And Company 5-HT1F agonists in chronic pain
EP0875513A1 (en) * 1997-04-14 1998-11-04 Eli Lilly And Company Substituted heteroaromatic 5-HT 1F agonists
ID23053A (id) * 1997-06-04 2000-01-20 Lilly Co Eli Karboksamida yang digunakan sebagai agonis 5-ht <if>
US6221884B1 (en) 1997-06-04 2001-04-24 Eli Lilly And Company Carboxamides useful as 5-HT1F agonists
US6380201B1 (en) 1997-08-05 2002-04-30 Eli Lilly And Company Methods of treating or ameliorating the symptoms of common cold or allergic rhinitis with serotonin 5-HT1F agonists
WO1999007700A1 (en) * 1997-08-09 1999-02-18 Smithkline Beecham Plc Bicyclic compounds as ligands for 5-ht1 receptors
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
ZA989389B (en) * 1997-11-14 2000-04-14 Lilly Co Eli Pyrrolo [3,2-b] pyridine processes and intermediates.
US5905084A (en) * 1997-11-14 1999-05-18 Eli Lilly And Company 5-HTIF -agonists effective in treating migraine
US6861448B2 (en) * 1998-01-14 2005-03-01 Virtual Drug Development, Inc. NAD synthetase inhibitors and uses thereof
DE69918799D1 (de) 1998-01-14 2004-08-26 Uab Res Foundation Birmingham Verfahren zur herstellung und screening von inhibitoren des bakteriellen nad synthetase enzyms, verbindungen daraus und methoden zur behandlung bakterieller und mikrobieller infektionen mit diesen inhibitoren
US6673827B1 (en) 1999-06-29 2004-01-06 The Uab Research Foundation Methods of treating fungal infections with inhibitors of NAD synthetase enzyme
CZ300706B6 (cs) * 1998-03-31 2009-07-22 The Institutes For Pharmaceutical Discovery, Inc. Derivát indolalkanové kyseliny a lécivo pro prevenci nebo zmírnení chronických komplikací vznikajících z diabetes mellitus
WO1999051592A1 (en) * 1998-04-08 1999-10-14 American Home Products Corporation Indol-3-yl-cyclohexyl amine derivatives for the treatment of depression (5-ht1 receptor antagonists)
US6204274B1 (en) 1998-04-29 2001-03-20 American Home Products Corporation Indolyl derivatives as serotonergic agents
US6310066B1 (en) 1998-04-29 2001-10-30 American Home Products Corp. Antipsychotic indolyl derivatives
US6066637A (en) * 1998-06-19 2000-05-23 American Home Products Corporation Indolyl derivatives as serotonergic agents
WO2000000490A2 (en) * 1998-06-26 2000-01-06 Eli Lilly And Company 5-ht1f agonists
US6133290A (en) * 1998-07-31 2000-10-17 Eli Lilly And Company 5-HT1F agonists
WO2000034266A1 (en) * 1998-12-11 2000-06-15 Eli Lilly And Company Indole derivatives and their use as 5-ht1f agonists
JP2002534426A (ja) * 1999-01-07 2002-10-15 ワイス 鬱病の処置のための新規な１，４−二基置換されたシクロヘキサン誘導体
US6200994B1 (en) 1999-01-07 2001-03-13 American Home Products Corp 1,4-Disubstituted cyclohexane derivatives for the treatment of depression
EP1153013B1 (en) * 1999-02-10 2007-10-31 Eli Lilly And Company 5-ht1f agonists
US6777428B1 (en) 1999-02-10 2004-08-17 Eli Lilly And Company 5-HT1f agonist
ES2214256T3 (es) * 1999-02-26 2004-09-16 Eli Lilly And Company Furo(3,2-b)piridinas como agonistas de 5-ht1f.
US6696439B1 (en) 1999-02-26 2004-02-24 Eli Lilly And Company 5-HT1F agonists
JP2003509509A (ja) * 1999-09-09 2003-03-11 ハー・ルンドベック・アクチエゼルスカベット ５−アミノアルキル及び５−アミノカルボニル置換されたインドール類
AU2002236730B2 (en) * 2001-01-30 2006-06-15 Eli Lilly And Company Benzenesulfonic acid indol-5-yl esters as antagonists of the 5-HT6 receptor
ES2187300B1 (es) * 2001-11-14 2004-06-16 Laboratorios Del Dr. Esteve, S.A. Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.
TWI263497B (en) 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
AU2003224257A1 (en) * 2002-04-09 2003-10-27 Astex Technology Limited Heterocyclic compounds and their use as modulators of p38 map kinase
AU2003287160A1 (en) * 2002-10-15 2004-05-04 Rigel Pharmaceuticals, Inc. Substituted indoles and their use as hcv inhibitors
JP2006523692A (ja) 2003-04-18 2006-10-19 イーライ リリー アンド カンパニー ５−ｈｔ１ｆ作用薬としての（ピペリジニルオキシ）フェニル、（ピペリジニルオキシ）ピリジニル、（ピペリジニルスルファニル）フェニル、および（ピペリジニルスルファニル）ピリジニル化合物
DE602004016491D1 (de) * 2003-05-09 2008-10-23 Esteve Labor Dr Verwendung von sulfonamid-derivate zur herstellung eines medikaments für die vorbeugung oder behandlung von essstörungen
ES2219181B1 (es) * 2003-05-09 2005-12-16 Laboratorios Del Dr. Esteve, S.A. Uso de derivados de sulfonamidas para la fabricacion de un medicamento para la profilaxis y/o tratamiento de las disfunciones alimentarias.
ES2222829B1 (es) 2003-07-30 2006-03-01 Laboratorios Del Dr. Esteve, S.A. Derivados de 4-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos.
ES2222832B1 (es) 2003-07-30 2006-02-16 Laboratorios Del Dr. Esteve, S.A. Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos.
UA82711C2 (en) 2003-09-12 2008-05-12 Эли Лилли Энд Компани Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists
ATE370116T1 (de) 2003-12-17 2007-09-15 Lilly Co Eli Substituierte (4-aminocyclohexen-1-yl) phenyl and (4-aminocyclohexen-1-yl) pyridinyl verbindungen als 5-ht1f agonisten
US7550499B2 (en) * 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
JP2008527043A (ja) * 2005-01-19 2008-07-24 ブリストル−マイヤーズ スクイブ カンパニー 血栓塞栓障害治療用のｐ２ｙ１受容体阻害剤としての２−フェノキシ−ｎ−（１，３，４−チアジアゾール−２−イル）ピリジン−３−アミン誘導体および関連化合物
EP1883451B9 (en) 2005-04-13 2011-02-09 Neuraxon Inc. Substituted indole compounds having nos inhibitory activity
US7714002B2 (en) * 2005-06-27 2010-05-11 Bristol-Myers Squibb Company Carbocycle and heterocycle antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
WO2007002635A2 (en) * 2005-06-27 2007-01-04 Bristol-Myers Squibb Company C-linked cyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
US7728008B2 (en) * 2005-06-27 2010-06-01 Bristol-Myers Squibb Company N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
WO2007002584A1 (en) 2005-06-27 2007-01-04 Bristol-Myers Squibb Company Linear urea mimics antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
WO2007118314A1 (en) * 2006-04-13 2007-10-25 Neuraxon, Inc. 1,5 and 3,6- substituted indole compounds having nos inhibitory activity
US7960569B2 (en) * 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
CA2705422A1 (en) * 2007-11-16 2009-05-22 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for treating visceral pain
CA2705833A1 (en) * 2007-11-16 2009-05-22 Subhash C. Annedi 3,5-substituted indole compounds having nos and norepinephrine reuptake inhibitory activity
CA2705835A1 (en) * 2007-11-16 2009-05-22 Neuraxon, Inc. Indole compounds and methods for treating visceral pain
CN102753171A (zh) * 2009-04-02 2012-10-24 科鲁西德制药公司 2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲酰胺的组合物
US8697876B2 (en) 2010-04-02 2014-04-15 Colucid Pharmaceuticals, Inc. Compositions and methods of synthesis of pyridinolypiperidine 5-HT1F agonists
US9707215B2 (en) 2012-06-20 2017-07-18 Cocrystal, Discovery, Inc. Inhibitors of hepatitis C virus polymerase
EP3027603B1 (en) * 2013-08-02 2018-07-18 Pfizer Inc Heterobicycloaryl rorc2 inhibitors and methods of use thereof
MA40759A (fr) 2014-09-26 2017-08-01 Pfizer Modulateurs de rorc2 de type pyrrolopyridine substitué par un méthyle et trifluorométhyle et leurs procédés d'utilisation
TWI731854B (zh) 2015-03-23 2021-07-01 美商共結晶製藥公司 Ｃ型肝炎病毒聚合酶之抑制劑
US11014892B2 (en) 2016-11-02 2021-05-25 Musc Foundation For Research Development 5HT1F receptor agonists and mitochondrial biogenesis
TWI826514B (zh) 2018-09-04 2023-12-21 美商美國禮來大藥廠 用於預防偏頭痛之拉米迪坦(lasmiditan)長期夜間投藥
AR119319A1 (es) 2019-07-09 2021-12-09 Lilly Co Eli Procesos e intermediario para la preparación a gran escala de hemisuccinato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbonil)-piridin-2-il]-benzamida y preparación de acetato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbonil)-piridin-2-il]-benzamida
CN113336633B (zh) * 2021-05-14 2022-12-06 武汉工程大学 一种5-羟基-2-萘满酮的合成方法
CN113233964A (zh) * 2021-05-14 2021-08-10 武汉工程大学 一种5-甲氧基-2-萘满酮的合成方法
CN114539120A (zh) * 2022-03-09 2022-05-27 台州学院 一种吲哚类钾离子通道激动剂的制备方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2193584B1 (es) * 1972-07-28 1975-08-08 Roussel Uclaf
FR2421899A1 (fr) * 1978-01-16 1979-11-02 Roussel Uclaf Nouveaux derives du tetrahydropyridinyl-indole et leurs sels, le procede de preparation et l'application a titre de medicaments de ces nouveaux produits
US4359468A (en) * 1981-02-25 1982-11-16 Boehringer Ingelheim Ltd. Antiallergic N-[4-(indolyl)-piperidino-alkyl]-benzimidazolones
FR2533924A1 (fr) * 1982-10-05 1984-04-06 Roussel Uclaf Nouveaux derives du 4-(1h-indol-3-yl)a-methyl piperidine-1-ethanol, leurs sels, le procede de preparation, l'application a titre de medicaments et les compositions les renfermant
IE58370B1 (en) * 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
US4742057A (en) * 1985-12-05 1988-05-03 Fujisawa Pharmaceutical Co., Ltd. Antiallergic thiazole compounds
JPH0633252B2 (ja) * 1987-08-13 1994-05-02 グラクソ、グループ、リミテッド インドール誘導体
GB8719167D0 (en) * 1987-08-13 1987-09-23 Glaxo Group Ltd Chemical compounds
DK733788A (da) * 1988-01-14 1989-07-15 Fujisawa Pharmaceutical Co Indolylpiperidinderivater og fremgangsmaade til fremstilling deraf
GB8819024D0 (en) * 1988-08-10 1988-09-14 Glaxo Group Ltd Chemical compounds
GB8900382D0 (en) * 1989-01-09 1989-03-08 Janssen Pharmaceutica Nv 2-aminopyrimidinone derivatives
GB8903036D0 (en) * 1989-02-10 1989-03-30 Glaxo Group Ltd Chemical compounds
IL96891A0 (en) * 1990-01-17 1992-03-29 Merck Sharp & Dohme Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them
HU219974B (hu) * 1990-06-07 2001-10-28 Astrazeneca Ab, Heterociklusos csoporttal helyettesített indolszármazék, előállítása és a vegyületet hatóanyagként tartalmazó gyógyszerkészítmények
US5322851A (en) * 1990-07-02 1994-06-21 H. Lundbeck A/S Indole derivatives
DK158590D0 (da) * 1990-07-02 1990-07-02 Lundbeck & Co As H Indolderivater
US5118691A (en) * 1990-09-20 1992-06-02 Warner-Lambert Co. Substituted tetrahydropyridines as central nervous system agents
US5187280A (en) * 1990-09-20 1993-02-16 Warner-Lambert Company Substituted tetrahydropyridines and their use as central nervous system agents
US5545644A (en) * 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
HU225055B1 (en) * 1990-10-15 2006-05-29 Pfizer Indole derivatives, their intermediates, process for production them and pharmaceutical compositions containing the compounds
SK278998B6 (sk) * 1991-02-01 1998-05-06 Merck Sharp & Dohme Limited Deriváty imidazolu, triazolu a tetrazolu, spôsob i
TW263508B (es) * 1991-02-12 1995-11-21 Pfizer
EP0619805B1 (en) * 1991-11-25 2000-03-15 Pfizer Inc. 5-(hetero- or carbocyclylamino)-indole derivatives, their preparation and their use as 5-ht1 agonists
GB9201089D0 (en) * 1992-01-18 1992-03-11 Scient Generics Ltd A diagnostic article
IL106445A (en) * 1992-07-30 1998-01-04 Merck Sharp & Dohme History of 1,2,4-Trans-Triazole 4-Transform, Preparation and Pharmaceutical Preparations Containing Them
TW251284B (es) * 1992-11-02 1995-07-11 Pfizer
GB9226532D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
HUT73807A (en) * 1993-04-22 1996-09-30 Pfizer Res & Dev 5-ht1-like indole derivatives and pharmaceutical compositions containing them
FR2705346B1 (fr) * 1993-05-18 1995-08-11 Union Pharma Scient Appl Nouveaux dérivés de pipéridinyl thio indole, leurs procédés de préparation, compositions pharmaceutiques les contenant, utiles notamment comme antalgiques .
US5521197A (en) * 1994-12-01 1996-05-28 Eli Lilly And Company 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists

Also Published As

Publication number Publication date
EP0733628B9 (en) 2002-06-12
AU5311296A (en) 1996-10-08
MX9706969A (es) 1997-11-29
WO1996029075A1 (en) 1996-09-26
DK0733628T3 (da) 2001-02-05
DE69611315T2 (de) 2001-05-31
JPH11502816A (ja) 1999-03-09
EA001113B1 (ru) 2000-10-30
ATE198332T1 (de) 2001-01-15
NO974220D0 (no) 1997-09-12
KR19980703048A (ko) 1998-09-05
NZ305166A (en) 1998-12-23
EP0733628B1 (en) 2000-12-27
HUP9800417A3 (en) 2001-04-28
HUP9800417A2 (hu) 1999-06-28
GR3035487T3 (en) 2001-05-31
CN1184425A (zh) 1998-06-10
SI0733628T1 (en) 2001-06-30
CA2215322A1 (en) 1996-09-26
BR9601061A (pt) 1998-01-06
EP0733628A1 (en) 1996-09-25
AU702322B2 (en) 1999-02-18
US5708008A (en) 1998-01-13
EA199700251A1 (ru) 1998-04-30
US5962474A (en) 1999-10-05
NO974220L (no) 1997-11-04
CZ288897A3 (cs) 1998-02-18
TR199700993T1 (xx) 1998-03-21
ES2153078T3 (es) 2001-02-16
DE69611315D1 (de) 2001-02-01
PT733628E (pt) 2001-06-29
PL322843A1 (en) 1998-02-16

Similar Documents

Publication Publication Date Title
AR002971A1 (es) COMPUESTOS DE 3-(1,2,3,6)-TETRAHIDROPIRIDIN-4-ILO Y 3-PIPERIDIN-4-ILO-1H- INDOL, AGONISTAS DE 5HT(1f) FORMULACIONES FARMACEUTICAS QUE LOS CONTIENEN YMETODOS PARA ACTIVAR DICHOS RECEPTORES 5HT(1f) Y/O PARA TRATAR LAS MIGRANAS Y DESORDENES ASOCIADOS CON ELLA.
PA8593101A1 (es) Composiciones para el tratamiento de crecimiento celular anormal
CO5560573A2 (es) Derivados activos de amino-ftalazinona como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los contienen
PE20020544A1 (es) Derivados de indolilmaleimida
NO20060973L (no) Pyridylderivater og deres anvendelse som tempeutiske midler
PE20021089A1 (es) Compuestos de triazol como inhibidores de las citoquinas
TW200626148A (en) Heterocyclic derivatives and their use as therapeutic agents
PE20011371A1 (es) Derivados de 3-(3-isopropil-5-metil-4h-1,2,4-triazol-4-il)-exo-8-azabiciclo[3.2.1]octano como antagonistas de los receptores de quimiocina ccr5
AR029383A1 (es) Moleculas pequenas, los intermediarios para su sintesis, las composiciones farmaceuticas que las contienen y su uso para preparar un medicamento destinado al tratamiento o la profilaxis de enfermedades inflamatorias o mediadas por celulas inmunes
PE20071136A1 (es) Derivados de anilina sustituida como antagonistas de la histamina h3
PE20060363A1 (es) DERIVADOS DE TETRAAZABENZO[e]AZULENO Y SUS ANALOGOS
CO5640136A2 (es) Derivados de hexahidropiridoisoquinolinas inhibidores de dpp-iv y composiciones farmaceuticas que los contienen
AR036492A1 (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3, composiciones farmaceuticas y el uso de dichos inhibidores para la elaboracion de un medicamento para el tratamiento de enfermedades androgeno dependientes
TW200626572A (en) Heterocyclic derivatives and their use as therapeutic agents
AR025225A1 (es) Feniloxazolidinonas heterociclicas biciclicas sustituidas antibacterianas y composiciones farmacéuticas
AR036042A1 (es) Derivados aralquilsufonil-3-(pirrol-2-ilmetiliden)-2-indolinona, sus composiciones farmaceuticas y metodo para la modulacion de la actividad catalitica de una proteina quinasa
PE20040898A1 (es) Nuevos compuestos derivados de pirimidina
PL313075A1 (en) Heterocyclic compounds used as antagonistic substances in respect to neurokinin
NO20006282L (no) Nye cyklosporiner
NO992770L (no) Nye heterocyklisk substituerte benzamider og deres anvendelse ved bekjempelse av sykdommer
NO20055977L (no) Nye benzimidazolderivater
NO20054340L (no) Nye sammenkoplede heterocykler og deres anvendelse
PE20050587A1 (es) Derivados de diazindol-dicarbonilo-piperazinilo como agentes antivirales
AR068695A2 (es) Uso de un compuesto de tiazol que comprende un derivado de tiazol para la fabricacion de un medicamento para la prevencion y el tratamiento de en-fermedades causadas por la produccion anormal de citocinas y/o la acele-racion de la adhesion de neutrofilos y/o la produccion anormal de tnf- alfa
NO20060147L (no) Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav